The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world population.
Hans M WestgeestM C P KuppenA J M van den EertweghR de WitA M BergmanR J A van MoorselaarJ L L M CoenenA C M van den BerghDiederik M SomfordNiven MehraInge M van OortK K H AbenMaarten J van der DoelenC A Uyl-de GrootPublished in: Prostate cancer and prostatic diseases (2021)
Since 2010, a larger proportion of mCRPC patients was treated with LPDs, which was related to an increased mOS.